[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343204-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343204-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-clinical-and-genetic-landscape-of-hereditary-cancer-experience-from-a-single-clinical-diagnostic-laboratory","The Clinical and Genetic Landscape of Hereditary Cancer: Experience from a Single Clinical Diagnostic Laboratory","","Next-generation sequencing (NGS) supports genetic investigation of hereditary cancer for clinical surveillance, therapeutic decision-making, and reducing the risk of developing new malignancies. The study analyzed genetic predisposition in 8,261 individuals referred for hereditary cancer between 2020 and 2023 using multigene testing, and performed whole exome sequencing in a subgroup of 85 women with breast cancer. Overall, 20% carried pathogenic variants, including pathogenic genes and CNV findings, supporting comprehensive multigene testing for clinical management and familial risk assessment.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-clinical-and-genetic-landscape-of-hereditary-cancer-experience-from-a-single-clinical-diagnostic-laboratory/343204/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-clinical-and-genetic-landscape-of-hereditary-cancer-experience-from-a-single-clinical-diagnostic-laboratory/343204.png","ImageObject",300,407,{"name":42,"@type":43},"Levi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What technology was used to investigate hereditary cancer genetics in this study?","Question",{"text":63,"@type":64},"The study used next-generation sequencing (NGS) with multigene genetic testing, and it also performed whole exome sequencing analysis in 85 women with breast cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many individuals were referred and tested for multigene genetic analysis?",{"text":68,"@type":64},"A total of 8,261 individuals were referred for multigene genetic testing during 2020–2023 and underwent testing using NGS.",{"name":70,"@type":61,"acceptedAnswer":71},"What proportion of the examined individuals carried pathogenic variants?",{"text":72,"@type":64},"The results showed that 20% of examined individuals carried a pathogenic variant, with a substantial fraction involving clinically significant genes and a portion representing copy number variation (CNV).","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343204,1790377557,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":109,"preview_page_count":33,"preview_urls":146},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","CANCER GENOMICS & PROTEOMICS 21: 448-463 (2024) doi:10.21873/cgp.20463  \nThe Clinical and Genetic Landscape of Hereditary Cancer: Experience from a Single Clinical Diagnostic Laboratory  \nNIKOLAOS TSOULOS 1 , KONSTANTINOS AGIANNITOPOULOS 1 , KEVISA POTSKA 1 , ANASTASIA KATSELI 1 , CHRISTINA NTOGKA 1 , GEORGIA PEPE 1 , DIMITRA BOUZARELOU 1 , ATHANASIOS PAPATHANASIOU 1 , DIMITRIOS GRIGORIADIS 1 , GEORGIOS N. TSAOUSIS 1 , HELEN GOGAS2 , THEODORE TROUPIS3 , KONSTANTINOS PAPAZISIS4 , IOANNIS NATSIOPOULOS5 , VASSILEIOS VENIZELOS6 , KYRIAKOS AMARANTIDIS7 , STYLIANOS GIASSAS8 , CHRISTOS PAPADIMITRIOU9 , ELENA FOUNTZILAS 10 , MAROULIO STATHOULOPOULOU6 , ANNA KOUMARIANOU 11 , GRIGORIOS XEPAPADAKIS8 , ALEXANDRU BLIDARU 12 , DANIELA ZOB 13 , OANA VOINEA 14 , MUSTAFA ÖZDOĞAN15 , MAHMUT ÇERKEZ ERGÖREN 16 , ALINTA HEGMANE 17 , EIRINI PAPADOPOULOU 1 , GEORGE NASIOULAS 1 and CHRISTOS MARKOPOULOS3  \n1Genekor Medical S.A, Athens, Greece;  \n2First Department of Medicine, National and Kapodistrian University of Athens-School of Medicine, Athens, Greece;  \n3School of Medicine, National and Kapodistrian University of Athens, Athens, Greece;  \n4Euromedica General Clinic, Thessaloniki, Greece;  \n5Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece;  \n6Metropolitan Hospital, Athens, Greece;  \n7Department of Medical Oncology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece;  \n8IASO, General Maternity and Gynecology Clinic, Athens, Greece;  \n9Oncology Unit, Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, Greece;  \n10Department of Medical Oncology, St. Lukes's Clinic, Thessaloniki, Greece;  \n11Section of Medical Oncology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece;  \n12Saint Constantin Hospital, Brasov, Romania;  \n13Oncology Department, \"Prof. Dr. Al. Trestioreanu\" Bucharest Oncology Institute, Bucharest, Romania;  \n14Department of Pathology, \"Carol Davila\" University of Medicine and Pharmacy, Bucharest, Romania;  \n15Division of Medical Oncology, Memorial Antalya Hospital, Antalya, Turkey;  \n16Department of Medical Genetics, Faculty of Medicine, Near East University, Nicosia, Cyprus;  \n17Riga East University Hospital, Oncology Center of Latvia, Riga, Latvia  \nAbstract. Background/Aim: The application of nextgeneration sequencing (NGS) technology in the genetic investigation of hereditary cancer is important for clinical surveillance, therapeutic approach, and reducing the risk of  \nCorrespondence to: Dr. Konstantinos Agiannitopoulos, Ph.D. , Genekor  \nMedical S.A, Athens, [Greece. E-mail: kagiannitopoulos@genekor.com](Greece. E-mail: kagiannitopoulos@genekor.com)  \n[Key Words:](Key Words: Hereditary cancer)[ Hereditary cancer](Key Words: Hereditary cancer), next generation sequencing, whole exome sequencing.  \nThis article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license ([https://creativecommons.org/licenses/by-nc-nd/4.0](https://creativecommons.org/licenses/by-nc-nd/4.0)).  \ndeveloping new malignancies. The aim of the study was to explore genetic predisposition in individuals referred for hereditary cancer. Materials and Methods: A total of 8,261 individuals were referred for multigene genetic testing, during the period 2020-2023, in the laboratory, and underwent multigene genetic testing using NGS. Among the examined individuals, 56.17% were diagnosed with breast cancer, 6. 77% with ovarian cancer, 2. 88% with colorectal cancer, 1.91% with prostate cancer, 6.43% were healthy with a significant family history of cancer, while 3.06% had a different type of cancer and 0.21% had not provided any information. Additionally, in 85 women with breast cancer we performed whole exome sequencing analysis. Results: 20% of the examined individuals carried a pathogenic variant. Specifically, 54.8% of the patients had a pathogenic variant  \nin a cli","cbCaipkz9N3TePRz","https://ap.wps.com/l/cbCaipkz9N3TePRz","pdf",3079367,16,"English","# Abstract\n## Background/Aim\n## Materials and Methods\n## Results\n## Conclusion","[{\"question\":\"What technology was used to investigate hereditary cancer genetics in this study?\",\"answer\":\"The study used next-generation sequencing (NGS) with multigene genetic testing, and it also performed whole exome sequencing analysis in 85 women with breast cancer.\"},{\"question\":\"How many individuals were referred and tested for multigene genetic analysis?\",\"answer\":\"A total of 8,261 individuals were referred for multigene genetic testing during 2020–2023 and underwent testing using NGS.\"},{\"question\":\"What proportion of the examined individuals carried pathogenic variants?\",\"answer\":\"The results showed that 20% of examined individuals carried a pathogenic variant, with a substantial fraction involving clinically significant genes and a portion representing copy number variation (CNV).\"}]","The Clinical and Genetic Landscape of Hereditary Cancer: Experience from a Single Clinical Diagnostic Laboratory | PDF",1790050282,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29f0e885f0e80b1cb87c5e2da83d6577.webp",983,1301,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/045ede731e9761d3c0fe053a7f4a3720.webp",982,1299,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9fe481d17a572816738240dc248d0ebd.webp",981,1298,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d3b960dd323bc6d88de18ece4591f5c7.webp",980,1297]